Aug 3, 2007 by Brian Orelli, PhDWatson Turns It AroundSteady revenue growth results in positive income for the quarter.
Aug 3, 2007 by Brian Orelli, PhDAnother Headache for Pozen InvestorsThe drugmaker might have to run one more trial for the FDA for its migraine drug.
Aug 2, 2007 by Brian Orelli, PhDMonsanto Counts BeansThe agricultural giant is one step closer to launching its new soybean.
Aug 2, 2007 by Brian Orelli, PhD98 Lawsuits Down, About 15,000 to GoMerck's Vioxx caseload just got a little smaller.
Aug 1, 2007 by Brian Orelli, PhDRNAi Gets Pumped UpIs using a medical device to deliver RNAi the next step in this technology?
Aug 1, 2007 by Brian Orelli, PhDBaxter's FDA TroublesThat's right, troubles, as in more than just one.
Jul 31, 2007 by Brian Orelli, PhDGPC Takes a Pit StopThe biotech company pulls its New Drug Application for Satraplatin.
Jul 30, 2007 by Brian Orelli, PhDMega Mylan Is on TrackIt's one merger down, one to go for the generic drug company.
Jul 30, 2007 by Brian Orelli, PhDPalomar PlummetsInvestors can't look past the loss of royalty payments.
Jul 30, 2007 by Brian Orelli, PhDIs Par Pharmaceutical Settling for Less?The generic drugmaker avoids going to court in some recent cases.
Jul 30, 2007 by Brian Orelli, PhDAnother Blow to Gene TherapyThe FDA shuts down a clinical trial, tripping up Targeted Genetics and possibly its competitors.
Jul 30, 2007 by Brian Orelli, PhDWhy Sepracor Investors Can't SleepFlat sales and increasing costs are not a good combination.
Jul 30, 2007 by Brian Orelli, PhDGlaxo Puffs Up TargaceptThe drug developers' partnership could be worth $1.5 billion.
Jul 27, 2007 by Brian Orelli, PhDStability From a Likely SourceBecton Dickinson's earnings are solid.
Jul 26, 2007 by Brian Orelli, PhDAffymetrix AdvancesNew products and services should help it regain market share.
Jul 25, 2007 by Brian Orelli, PhDHopeful Flu Production Technology From BaxterPandemic flu and the regular old make-you-sick kind.
Jul 25, 2007 by Brian Orelli, PhDOn to the FDA With a New NameAfter four phase 3 clinical trials, Advanced Magnetics is ready to submit a New Drug Application.
